Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...

Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...

In two cohorts from the UK Biobank and the National Health and Nutrition Examination Survey (NHANES), there was an increased ...

Machine learning (ML) models developed by Lehmann and colleagues used driving characteristics and head motion data to detect ...

In a randomized double-blind placebo-controlled study, naldemedine use was associated with constipation prevention and a ...

In veterans with spinal cord injuries, exoskeletons showed no clear benefits (medical, physical or psychological) compared to ...

In this cohort study involving noncirrhotic patients with chronic hepatitis B, a new prognostic model based on viral load was ...

Chronic pain syndromes including fibromyalgia, dry eye disease, and irritable bowel syndrome showed no significant ...

Relutrigine resulted in a 46% reduction in seizures and seizure freedom in 30% of patients. Patients also experienced ...

Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...

1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the ...

1. In this retrospective observational cohort study of children in St. Louis, those with the highest risk of firearm injury ...